An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Pharmacies and doctors are reporting a big increase in prescriptions for two popular weight-loss drugs, semaglutide and tirzepatide, in the first quarter of 2025. The headline is about growth in how often these drugs are being prescribed, not about a new drug approval or a new safety finding. In short: more people are being started on—or continuing—these medicines than before. Semaglutide and tirzepatide are the active ingredients inside brand-name shots people often call Ozempic, Wegovy, and Zepbound (and others). They are man-made versions of hormones your body uses to regulate hunger and blood sugar. Semaglutide mimics a gut hormone that tells your brain you’re full and also slows how fast the stomach empties. Tirzepatide works on two similar hormone pathways, so it can reduce appetite and help control blood sugar too. The reports about prescription growth are based on prescription data—how many scripts were written or filled—rather than a clinical trial. That means the “study” is observational: it simply counts use, not whether the drugs work better or are safer than before. Growth can be big in percent terms but still reflect different absolute numbers depending on the starting point. The data don’t tell us about individual patient outcomes, how long people stayed on the drugs, or whether new users met medical criteria for treatment. Why this matters: rising prescriptions affect many people. Patients who have been helped by these drugs may find access easier if more clinics and insurers accept them. On the flip side, increased demand can strain supply chains, raise prices, or lead to tighter insurance rules about who qualifies. Doctors, insurers, and policymakers pay attention because these trends influence public health planning, budget forecasts, and how widely these medicines become part of routine care for obesity and diabetes. There are important caveats. Prescription counts don’t prove better safety or broader benefit; they only show usage. These medicines have real side effects—nausea, stomach upset, and rarely more serious problems—and they require medical supervision. Not everyone should take them, including people with certain medical histories (for instance, some cancers or pancreatitis risks), and they are prescription-only. Insurance coverage varies, and long-term effects are still being studied, especially when people use them for years. Finally, the growth trend doesn’t say whether the drugs are being used appropriately or off-label. Bottom line: more people are getting prescriptions for semaglutide and tirzepatide in early 2025, which signals growing use but doesn’t by itself answer questions about safety, effectiveness for every person, or whether this is sustainable.
Source: emy